Advanced

The potential of alternate sources of cells for neural grafting in Parkinson's and Huntington's disease

Drouin-Ouellet, Janelle LU (2014) In Neurodegenerative disease management 4(4). p.297-307
Abstract

Cell-based therapies for Parkinson's and Huntington's disease have provided mixed clinical outcomes and one of the reasons underlying this is the use of primary fetal tissue as the source of grafted cells. An alternate source of cells, such as stem cells, could overcome many of the issues associated with primary fetal tissue and would help bring forward cell replacement therapy as a reliable and effective treatment for these two neurodegenerative disorders. This review will discuss which stem cells are likely to go to clinic in the next generation of cells, based on trials for Parkinson's and Huntington's disease.

Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
keywords
Cell- and Tissue-Based Therapy, Fetal Research, Fibroblasts, Humans, Huntington Disease, Neurodegenerative Diseases, Pluripotent Stem Cells, Stem Cell Transplantation, Tissue Engineering, Journal Article, Research Support, Non-U.S. Gov't, Review
in
Neurodegenerative disease management
volume
4
issue
4
pages
11 pages
publisher
Future Medicine Ltd.
external identifiers
  • scopus:84928699326
ISSN
1758-2024
DOI
10.2217/nmt.14.26
language
English
LU publication?
no
id
64628f33-5c97-4f0e-82ca-e8f93a5e65eb
date added to LUP
2016-11-22 09:02:41
date last changed
2017-10-01 05:26:10
@article{64628f33-5c97-4f0e-82ca-e8f93a5e65eb,
  abstract     = {<p>Cell-based therapies for Parkinson's and Huntington's disease have provided mixed clinical outcomes and one of the reasons underlying this is the use of primary fetal tissue as the source of grafted cells. An alternate source of cells, such as stem cells, could overcome many of the issues associated with primary fetal tissue and would help bring forward cell replacement therapy as a reliable and effective treatment for these two neurodegenerative disorders. This review will discuss which stem cells are likely to go to clinic in the next generation of cells, based on trials for Parkinson's and Huntington's disease.</p>},
  author       = {Drouin-Ouellet, Janelle},
  issn         = {1758-2024},
  keyword      = {Cell- and Tissue-Based Therapy,Fetal Research,Fibroblasts,Humans,Huntington Disease,Neurodegenerative Diseases,Pluripotent Stem Cells,Stem Cell Transplantation,Tissue Engineering,Journal Article,Research Support, Non-U.S. Gov't,Review},
  language     = {eng},
  number       = {4},
  pages        = {297--307},
  publisher    = {Future Medicine Ltd.},
  series       = {Neurodegenerative disease management},
  title        = {The potential of alternate sources of cells for neural grafting in Parkinson's and Huntington's disease},
  url          = {http://dx.doi.org/10.2217/nmt.14.26},
  volume       = {4},
  year         = {2014},
}